Male Genital Cancer Centre, Department of Urology, University College London Hospitals NHS Trust, London, UK.
Università Vita-Salute San Raffaele, Milan, Italy.
World J Urol. 2023 Jun;41(6):1581-1588. doi: 10.1007/s00345-023-04396-x. Epub 2023 Apr 5.
To describe our surgical technique and report the oncological outcomes and complication rates using a fascial-sparing radical inguinal lymphadenectomy (RILND) technique for penile cancer patients with cN+ disease in the inguinal lymph nodes.
Over a 10-year period, 660 fascial-sparing RILND procedures were performed in 421 patients across two specialist penile cancer centres. The technique used a subinguinal incision with an ellipse of skin excised over any palpable nodes. Identification and preservation of the Scarpa's and Camper's fascia was the first step. All superficial inguinal nodes were removed en bloc under this fascial layer with preservation of the subcutaneous veins and fascia lata. The saphenous vein was spared where possible. Patient characteristics, oncologic outcomes and perioperative morbidity were retrospectively collected and analysed. Kaplan-Meier curves estimated the cancer-specific survival (CSS) functions after the procedure.
Median (interquartile range, IQR) follow-up was 28 (14-90) months. A median (IQR) number of 8.0 (6.5-10.5) nodes were removed per groin. A total of 153 postoperative complications (36.1%) occurred, including 50 conservatively managed wound infections (11.9%), 21 cases of deep wound dehiscence (5.0%), 104 cases of lymphoedema (24.7%), 3 cases of deep vein thrombosis (0.7%), 1 case of pulmonary embolism (0.2%), and 1 case of postoperative sepsis (0.2%). The 3-year CSS was 86% (95%Confidence Interval [95% CI] 77-96), 83% (95% CI 72-92), 58% (95% CI 51-66), respectively, for the pN1, pN2 and pN3 patients (p < 0.001), compared to a 3-year CSS of 87% (95% CI 84-95) for the pN0 patients.
Fascial-sparing RILND offers excellent oncological outcomes whilst decreasing the morbidity rates. Patients with more advanced nodal involvement had poorer survival rates, emphasizing the need for adjuvant chemo-radiotherapy.
描述我们的手术技术,并报告使用筋膜保留根治性腹股沟淋巴结切除术(RILND)治疗腹股沟淋巴结 cN+期阴茎癌患者的肿瘤学结果和并发症发生率。
在两个专业的阴茎癌中心,在 10 年期间对 421 名患者进行了 660 例筋膜保留 RILND 手术。该技术采用腹股沟下切口,切除任何可触及淋巴结上方的椭圆形皮肤。首先识别和保留 Scarpa 筋膜和 Camper 筋膜。所有浅层腹股沟淋巴结均在该筋膜层下整块切除,同时保留皮下静脉和阔筋膜。在可能的情况下保留隐静脉。回顾性收集和分析患者特征、肿瘤学结果和围手术期发病率。Kaplan-Meier 曲线估计手术后的癌症特异性生存率(CSS)。
中位(四分位距,IQR)随访时间为 28(14-90)个月。每个腹股沟平均(IQR)切除 8.0(6.5-10.5)个淋巴结。共发生 153 例术后并发症(36.1%),包括 50 例保守治疗的伤口感染(11.9%)、21 例深部伤口裂开(5.0%)、104 例淋巴水肿(24.7%)、3 例深静脉血栓形成(0.7%)、1 例肺栓塞(0.2%)和 1 例术后败血症(0.2%)。pN1、pN2 和 pN3 患者的 3 年 CSS 分别为 86%(95%置信区间[95%CI] 77-96)、83%(95%CI 72-92)和 58%(95%CI 51-66)(p<0.001),而 pN0 患者的 3 年 CSS 为 87%(95%CI 84-95)。
筋膜保留 RILND 提供了优异的肿瘤学结果,同时降低了发病率。淋巴结受累程度较高的患者生存率较差,强调了辅助放化疗的必要性。